Tirzepatide
(GLP-1 / GIP Dual Incretin Receptor Agonist)
Tirzepatide is a next-generation investigational peptide designed to engage multiple metabolic pathways. It has become a leading compound of interest in incretin-focused research for its dual activity on key hormone receptors. Areas currently under investigation include:
-
Body Weight Regulation
Tirzepatide is being studied for its potential effects on fat mass reduction, appetite suppression, and energy balance. -
Glycemic Control
Researchers are exploring how Tirzepatide may improve insulin sensitivity and glucose regulation through incretin receptor signaling. -
Metabolic Resilience
Ongoing studies are examining its role in improving lipid metabolism, reducing inflammation, and supporting overall metabolic health.
How It Works
Tirzepatide functions as a dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. GLP-1 receptor activation supports insulin secretion, slows gastric emptying, and promotes satiety, while GIP receptor activation enhances the insulinotropic response and may modulate fat metabolism. The combined stimulation of both pathways is being researched for synergistic effects on appetite regulation, body composition, and glycemic control—making Tirzepatide a cutting-edge candidate in metabolic research.
⚠️ Important Notice:
This product is sold strictly for laboratory research purposes only. It is not for human or animal use, and not for therapeutic or diagnostic applications.
By purchasing, you confirm that you are a qualified individual using this product in accordance with all applicable laws and research regulations.
